RxDoctor Payments Data

Syed Sheheryar Ahmed Shah, MD

Nephrology · Pine Bluff, ARNPI 1174019905

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.7% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $879, more than ten times the $14 reported in 2023.

$1,575in general payments, 2019–2025

Across 73 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$302
  • Ardelyx, Inc.$256
  • Mallinckrodt Hospital Products Inc.$186
  • Travere Therapeutics, Inc.$183
  • AstraZeneca$152
  • Novartis$150
  • plus $347 from 7 others

What the payments were for

  • Food & beverage$1,49295%
  • Education$835%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,575 in reported general payments places this provider in the 55th percentile of 85 nephrology providers in Arkansas.

See all nephrology providers in Arkansas

Medicare billing

Part B allowed, 2024
$100,940
Medicare patients
278
Services billed
1,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin31$18,912
OzempicSemaglutide15$14,009
FarxigaDapagliflozin Propanediol17$9,592
Sevelamer Carbonate30$2,343
Bumetanide39$1,361
Nifedipine ErNifedipine41$468
Chlorthalidone50$377
Hydralazine Hcl31$203
Calcitriol13$153
Amlodipine Besylate28$112
Allopurinol21$86
Furosemide21$81
Potassium Chloride12$63
Losartan Potassium17$54
Lisinopril14$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$144$14,00915 claims
AstraZenecaFarxiga$152$9,59217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 85 nephrology providers in Arkansas.

Other nephrology in Pine Bluff

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →